ExploreWatchlistsPricing
  1. US-listed companies
  2. Akari Therapeutics Plc
  3. Financials
  4. Research & development

Akari Therapeutics Plc (AKTX)

Market cap
$531.1B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 20253-48.35%
Dec 31, 20235-43.00%
Dec 31, 202210+4.68%
Dec 31, 20219+3.55%
Dec 31, 20209+0.92%
Dec 31, 20199-25.91%
Dec 31, 201812-49.34%
Dec 31, 201723+34.55%
Dec 31, 201617+198.43%
Dec 31, 20156-9.63%
Dec 31, 20146-9.82%
Dec 31, 20137

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat